Arthur Sillah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arthur Sillah has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Polly A. Newcomb
Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington
9 shared publications - Adriana M. Reedy
Affiliation Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America
8 shared publications - Amanda I. Phipps
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington
8 shared publications - Courtney M. Hill
Department of Epidemiology, University of Washington, Seattle, Washington
8 shared publications - Hamza Ammar
Fred Hutchinson Cancer Center 1 Public Health Sciences Division Seattle, Washington
8 shared publications - Johanna W. Lampe
Public Health Sciences Division, Fred Hutchinson Cancer Center , 1100 Fairview Ave N, Seattle, WA 98109
8 shared publications
Latest Publications
- Open Access
- 21 October 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15  (1) , 51
Prevalence of Diagnosed Essential Tremor in the United States: An Administrative Claims-Based Study
Background: Essential tremor (ET) is one of the most common movement disorders. Previous estimates of ET prevalence vary due to multiple factors. This study estimated the prevalence of diagnosed ET. Methods: The prevalence of diagnosed ET was estimated among adults with continuous enrollment in 2022 and ≥1 additional year of prior baseline enrollment in the Merative™ MarketScan® Research Databases, a US administrative claims database. ET was defined as ≥2 ET claims within 12 months of one another during the 2016–2022 study period. The proportion of patients receiving treatment was defined as having a claim for possible medication for ET in 2022 among those with diagnosed ET who had an additional 6 months of follow-up following the first ET diagnosis claim. Age-standardized estimates of the number of US adults with diagnosed ET were calculated using 2024 US population census projections. Results: The prevalence of diagnosed ET was 0.28% before age standardization, ranging from 0.06% (18–40 years) to 1.61% (≥75 years); 74% of patients overall received possible treatment. After standardization, prevalence was 0.42%; in 2024, 1.1 million US adults were estimated to have diagnosed ET. Estimates of the prevalence of diagnosed ET in the US were susceptible to the choice of case definition, nearly doubling (ie, 2.1 million US adults) with a more sensitive definition. Discussion: ET affects a substantial proportion of the US adult population. Selecting appropriate case definitions and using methods such as standardization are critical for estimating valid and generalizable chronic condition prevalences with real-world data. Highlights This study found that 1.1 million US adults were estimated to have been diagnosed with essential tremor, with the sensitivity analyses yielding additional estimates. Estimating reliable and generalizable prevalences of diagnosed chronic conditions requires selection of appropriate case definitions and standardization to the general population.
- 21 October 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15  (1) , 51
Open AccessPrevalence of Diagnosed Essential Tremor in the United States: An Administrative Claims-Based Study
Background: Essential tremor (ET) is one of the most common movement disorders. Previous estimates of ET prevalence vary due to multiple factors. This study estimated the prevalence of diagnosed ET. Methods: The prevalence of diagnosed ET was estimated among adults with continuous enrollment in 2022 and ≥1 additional year of prior baseline enrollment in the Merative™ MarketScan® Research Databases, a US administrative claims database. ET was defined as ≥2 ET claims within 12 months of one another during the 2016–2022 study period. The proportion of patients receiving treatment was defined as having a claim for possible medication for ET in 2022 among those with diagnosed ET who had an additional 6 months of follow-up following the first ET diagnosis claim. Age-standardized estimates of the number of US adults with diagnosed ET were calculated using 2024 US population census projections. Results: The prevalence of diagnosed ET was 0.28% before age standardization, ranging from 0.06% (18–40 years) to 1.61% (≥75 years); 74% of patients overall received possible treatment. After standardization, prevalence was 0.42%; in 2024, 1.1 million US adults were estimated to have diagnosed ET. Estimates of the prevalence of diagnosed ET in the US were susceptible to the choice of case definition, nearly doubling (ie, 2.1 million US adults) with a more sensitive definition. Discussion: ET affects a substantial proportion of the US adult population. Selecting appropriate case definitions and using methods such as standardization are critical for estimating valid and generalizable chronic condition prevalences with real-world data. Highlights This study found that 1.1 million US adults were estimated to have been diagnosed with essential tremor, with the sensitivity analyses yielding additional estimates. Estimating reliable and generalizable prevalences of diagnosed chronic conditions requires selection of appropriate case definitions and standardization to the general population.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Table S1: Presence or Absence of the nusG Gene, detected by three different Primer and Probe Sets in the Genomes of Bacteria in the Genus Fusobacterium Available from NCBI.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Table S1: Presence or Absence of the nusG Gene, detected by three different Primer and Probe Sets in the Genomes of Bacteria in the Genus Fusobacterium Available from NCBI.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S5: Serial dilution of nusG gene copies added to human genomic DNA extracted from FFPE human tissue using qPCR.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S5: Serial dilution of nusG gene copies added to human genomic DNA extracted from FFPE human tissue using qPCR.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S3: Serial dilution of nusG gene copies added to human genomic DNA extracted from FFPE human tissue to determine the limit of detection (LOD) and limit of quantitation (LOQ) of nusG using ddPCR.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S3: Serial dilution of nusG gene copies added to human genomic DNA extracted from FFPE human tissue to determine the limit of detection (LOD) and limit of quantitation (LOQ) of nusG using ddPCR.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S4: Detection of a serial dilution of nusG template using qPCR systems for the assessment of linearity.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S4: Detection of a serial dilution of nusG template using qPCR systems for the assessment of linearity.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S2: ddPCR data viewed as 1-D plot, with fluorescence amplitude plots of FAM-labeled probe for Fusobacterium nucleatumnusG assay from 3 different studies
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S2: ddPCR data viewed as 1-D plot, with fluorescence amplitude plots of FAM-labeled probe for Fusobacterium nucleatumnusG assay from 3 different studies
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S1: Physical agitation increased genomic DNA yield.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Supplementary Figure S1: Physical agitation increased genomic DNA yield.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Background:Fusobacterium nucleatum (Fn) has been associated with the risk of colorectal cancer, poor colorectal cancer survival, and tumor attributes. Accurate and sensitive detection of Fn in tumor tissue is critical for evaluating their role in colorectal cancer.Methods:We developed a droplet digital PCR (ddPCR) assay for detecting Fn using the transcription termination/antitermination gene (nusG) normalized for host tissue (solute carrier organic anion transporter family member 2A1). We assayed Fn(nusG) in matched tumor and normal tissues for 613 participants in the Seattle site of the Colon Cancer Family Registry. We used logistic regression to determine the odds of Fn enrichment in tumor tissue according to the tumor site and stage, adjusting for age, sex, and body mass index.Results:The limit of quantitation for Fn(nusG) was 4.1 copies/10 ng host tissue. Detection of Fn was quenched and poor at low levels in formalin-fixed, paraffin-embedded tissues using qPCR. There was a low agreement between qPCR and ddPCR (Cohen’s kappa = 0.46). Fn(nusG) was detected in tumor (21%) and normal (10%) tissues and was enriched in 19% of tumors. Individuals with tumors enriched in Fn were more likely to be female (59% vs. 48%, respectively; P = 0.04) with proximal colon tumors (57% vs. 43%; P = 0.026). In multivariable-adjusted analyses, proximal colon tumors were significantly associated with Fn enrichment (OR vs. rectal tumors: 1.86; 95% confidence interval, 1.11–3.24).Conclusions:We established a sensitive and specific method to detect Fn enrichment in human tissues.Impact:ddPCR enhanced detection of Fn(nusG) for studies targeting tumor-associated bacteria.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Background:Fusobacterium nucleatum (Fn) has been associated with the risk of colorectal cancer, poor colorectal cancer survival, and tumor attributes. Accurate and sensitive detection of Fn in tumor tissue is critical for evaluating their role in colorectal cancer.Methods:We developed a droplet digital PCR (ddPCR) assay for detecting Fn using the transcription termination/antitermination gene (nusG) normalized for host tissue (solute carrier organic anion transporter family member 2A1). We assayed Fn(nusG) in matched tumor and normal tissues for 613 participants in the Seattle site of the Colon Cancer Family Registry. We used logistic regression to determine the odds of Fn enrichment in tumor tissue according to the tumor site and stage, adjusting for age, sex, and body mass index.Results:The limit of quantitation for Fn(nusG) was 4.1 copies/10 ng host tissue. Detection of Fn was quenched and poor at low levels in formalin-fixed, paraffin-embedded tissues using qPCR. There was a low agreement between qPCR and ddPCR (Cohen’s kappa = 0.46). Fn(nusG) was detected in tumor (21%) and normal (10%) tissues and was enriched in 19% of tumors. Individuals with tumors enriched in Fn were more likely to be female (59% vs. 48%, respectively; P = 0.04) with proximal colon tumors (57% vs. 43%; P = 0.026). In multivariable-adjusted analyses, proximal colon tumors were significantly associated with Fn enrichment (OR vs. rectal tumors: 1.86; 95% confidence interval, 1.11–3.24).Conclusions:We established a sensitive and specific method to detect Fn enrichment in human tissues.Impact:ddPCR enhanced detection of Fn(nusG) for studies targeting tumor-associated bacteria.
- 4 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34  (8) , OF1-OF9
Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Background: Fusobacterium nucleatum (Fn) has been associated with the risk of colorectal cancer, poor colorectal cancer survival, and tumor attributes. Accurate and sensitive detection of Fn in tumor tissue is critical for evaluating their role in colorectal cancer. Methods: We developed a droplet digital PCR (ddPCR) assay for detecting Fn using the transcription termination/antitermination gene (nusG) normalized for host tissue (solute carrier organic anion transporter family member 2A1). We assayed Fn(nusG) in matched tumor and normal tissues for 613 participants in the Seattle site of the Colon Cancer Family Registry. We used logistic regression to determine the odds of Fn enrichment in tumor tissue according to the tumor site and stage, adjusting for age, sex, and body mass index. Results: The limit of quantitation for Fn(nusG) was 4.1 copies/10 ng host tissue. Detection of Fn was quenched and poor at low levels in formalin-fixed, paraffin-embedded tissues using qPCR. There was a low agreement between qPCR and ddPCR (Cohen’s kappa = 0.46). Fn(nusG) was detected in tumor (21%) and normal (10%) tissues and was enriched in 19% of tumors. Individuals with tumors enriched in Fn were more likely to be female (59% vs. 48%, respectively; P = 0.04) with proximal colon tumors (57% vs. 43%; P = 0.026). In multivariable-adjusted analyses, proximal colon tumors were significantly associated with Fn enrichment (OR vs. rectal tumors: 1.86; 95% confidence interval, 1.11–3.24). Conclusions: We established a sensitive and specific method to detect Fn enrichment in human tissues. Impact: ddPCR enhanced detection of Fn(nusG) for studies targeting tumor-associated bacteria.
- 4 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34  (8) , OF1-OF9
Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors
Background: Fusobacterium nucleatum (Fn) has been associated with the risk of colorectal cancer, poor colorectal cancer survival, and tumor attributes. Accurate and sensitive detection of Fn in tumor tissue is critical for evaluating their role in colorectal cancer. Methods: We developed a droplet digital PCR (ddPCR) assay for detecting Fn using the transcription termination/antitermination gene (nusG) normalized for host tissue (solute carrier organic anion transporter family member 2A1). We assayed Fn(nusG) in matched tumor and normal tissues for 613 participants in the Seattle site of the Colon Cancer Family Registry. We used logistic regression to determine the odds of Fn enrichment in tumor tissue according to the tumor site and stage, adjusting for age, sex, and body mass index. Results: The limit of quantitation for Fn(nusG) was 4.1 copies/10 ng host tissue. Detection of Fn was quenched and poor at low levels in formalin-fixed, paraffin-embedded tissues using qPCR. There was a low agreement between qPCR and ddPCR (Cohen’s kappa = 0.46). Fn(nusG) was detected in tumor (21%) and normal (10%) tissues and was enriched in 19% of tumors. Individuals with tumors enriched in Fn were more likely to be female (59% vs. 48%, respectively; P = 0.04) with proximal colon tumors (57% vs. 43%; P = 0.026). In multivariable-adjusted analyses, proximal colon tumors were significantly associated with Fn enrichment (OR vs. rectal tumors: 1.86; 95% confidence interval, 1.11–3.24). Conclusions: We established a sensitive and specific method to detect Fn enrichment in human tissues. Impact: ddPCR enhanced detection of Fn(nusG) for studies targeting tumor-associated bacteria.
- Open Access
- 22 May 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6  (1) , e75127
Authors’ Response to Peer Reviews of “Prevalence and Determinants of Academic Bullying Among Junior Doctors in Sierra Leone: Cross-Sectional Study”
- 22 May 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6  (1) , e75127
Open AccessAuthors’ Response to Peer Reviews of “Prevalence and Determinants of Academic Bullying Among Junior Doctors in Sierra Leone: Cross-Sectional Study”